BioPharma Dive 2025年12月18日 Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial
Endpoints News 2025年12月18日 Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting
FierceBiotech 2025年12月11日 Lilly's obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some
Endpoints News 2025年12月11日 Lilly’s triple agonist posts strongest weight loss data yet, unusual skin side effect also reported
Endpoints News 2025年12月9日 #ASH25: Eli Lilly's Jaypirca makes first-line case, but ceiling may be capped
FierceBiotech 2025年12月8日 With weight loss windfall, Lilly looks to become ‘backbone’ of global innovation: exec
Endpoints News 2025年12月8日 Structure Therapeutics’ obesity pill stacks up with Novo and Lilly; Ascletis also reports early results